Literature DB >> 12601095

Major malformations in offspring of women with epilepsy.

Erja Kaaja1, Risto Kaaja, Vilho Hiilesmaa.   

Abstract

BACKGROUND: The offspring of women with epilepsy are at an increased risk of major congenital malformations, but the impact of the various contributing factors remains unresolved.
METHOD: In 1980 through 1998, the authors prospectively followed up 970 pregnancies in women with epilepsy at a single maternity clinic. Of their 979 offspring, 740 were exposed to maternal antiepileptic drugs (AED) during the first trimester of pregnancy and 239 were not exposed. Maternal AED levels and serum folate concentrations were measured at the end of the first trimester. Logistic regression analysis was applied to identify factors associated with the occurrence of major malformations in the fetuses and newborns.
RESULTS: Major malformations were detected in 28 fetuses (3.8%) exposed to maternal AED and in 2 (0.8%) not exposed (p = 0.02). After logistic regression analysis, the occurrence of major malformations was independently associated with use of carbamazepine (adjusted OR 2.5; 95% CI 1.0 to 6.0), use of valproate (4.1; 1.6 to 11), use of oxcarbazepine (10.8; 1.1 to 106), low serum folate concentration (5.8; 1.3 to 27), and low maternal level of education (3.0; 1.3 to 6.8). Major malformations were not associated with seizures during the first trimester (0.6; 0.1 to 2.9).
CONCLUSIONS: Major malformations in the offspring of mothers with epilepsy are associated with use of AED during early pregnancy, and also with low serum folate concentrations and a low level of education.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12601095     DOI: 10.1212/01.wnl.0000044157.28073.dc

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  41 in total

1.  NICE guidance on newer drugs for epilepsy in adults.

Authors:  Emilio Perucca
Journal:  BMJ       Date:  2004-05-29

2.  Using current evidence in selecting antiepileptic drugs for use during pregnancy.

Authors:  Page B Pennell
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

Review 3.  Major malformations with valproic acid.

Authors:  Gideon Koren; Alejandro A Nava-Ocampo; Myla E Moretti; Reuven Sussman; Irena Nulman
Journal:  Can Fam Physician       Date:  2006-04       Impact factor: 3.275

Review 4.  Epilepsy in pregnancy.

Authors:  Torbjörn Tomson; Vilho Hiilesmaa
Journal:  BMJ       Date:  2007-10-13

5.  In utero antiepileptic drug exposure: fetal death and malformations.

Authors:  K J Meador; G A Baker; R H Finnell; L A Kalayjian; J D Liporace; D W Loring; G Mawer; P B Pennell; J C Smith; M C Wolff
Journal:  Neurology       Date:  2006-08-08       Impact factor: 9.910

6.  [Antiepileptics in women of childbearing age and during pregnancy: comparison of specialized information with the current state of knowledge in Germany and Switzerland].

Authors:  U Winterfeld; V Gotta; L E Rothuizen; A Panchaud; A O Rossetti; T Buclin
Journal:  Nervenarzt       Date:  2014-06       Impact factor: 1.214

Review 7.  Management of epilepsy during pregnancy: an update.

Authors:  Sima I Patel; Page B Pennell
Journal:  Ther Adv Neurol Disord       Date:  2015-12-27       Impact factor: 6.570

Review 8.  Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?

Authors:  John J Craig
Journal:  Obstet Med       Date:  2012-02-20

Review 9.  Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts.

Authors:  Kimford Meador; Matthew W Reynolds; Sheila Crean; Kyle Fahrbach; Corey Probst
Journal:  Epilepsy Res       Date:  2008-06-18       Impact factor: 3.045

Review 10.  Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study.

Authors:  Janneke Jentink; Helen Dolk; Maria A Loane; Joan K Morris; Diana Wellesley; Ester Garne; Lolkje de Jong-van den Berg
Journal:  BMJ       Date:  2010-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.